How BioNTech, PanGenomic Health, and Pfizer are using artificial intelligence to cut costs and boost returns

BioNTech – New momentum in pipeline and partnerships

BioNTech is currently facing heavy losses, amounting to around EUR 416 million in the first quarter of 2025. This is due to massive investments in research and development, which alone swallowed up over EUR 0.5 billion in Q1. Revenues from the COVID-19 vaccine continue to decline, with sales at just under EUR 183 million, slightly below the previous year's level. Despite the red figures, the balance sheet remains robust. With almost EUR 16 billion in cash and cash equivalents, the Mainz-based company has sufficient financial resources to fund its ambitious plans in oncology and infectious diseases.

The strategic realignment is in full swing. The billion-dollar deal with Bristol Myers Squibb for the cancer antibody BNT327 not only brings in USD 1.5 billion in fresh capital, but also access to global marketing power. At the same time, the acquisition of mRNA specialist CureVac strengthens the portfolio, particularly in personalized cancer therapies and new vaccine approaches. These partnerships and acquisitions should help BioNTech replace declining COVID revenues with long-term therapy revenues.

Innovation at BioNTech is increasingly driven by AI. Its proprietary platform, DeepChain, uses complex biological data to accelerate drug design. This is supported by the Company's in-house supercomputer, "Kyber". In everyday laboratory work, the AI assistant "Laila" takes over routine tasks ranging from DNA analysis to equipment monitoring. These tools now permeate the entire pipeline. For investors, BioNTech is demonstrating how it is using its financial strength and technological base to grow beyond its pandemic-era successes. The stock is currently available for EUR 95.80.

PanGenomic Health – How digitalization and prevention are creating new opportunities

The US healthcare market is undergoing a digital revolution. Driven by skyrocketing treatment costs, which are the highest in the world at 16% of GDP, and the longevity hype, which is putting sustainable prevention at the center of attention, the digital health sector is growing rapidly. Market volumes of nearly USD 80 billion with double-digit growth rates underscore the potential. Telemedicine, wearables, and AI-powered diagnostics are becoming key solutions that not only give patients more control but also address system inefficiencies. This is where PanGenomic Health comes in, a Canadian innovator that skillfully combines these trends.

PanGenomic has evolved from a pandemic project to a tech pioneer, offering personalized prevention solutions with its NARA, Mindleap, and MUJN platforms. At its core is AI-powered Nustasis technology, which analyzes genetic profiles, lifestyle data, and neurological biomarkers to generate tailored health recommendations. Unlike pure telemedicine providers, the Company combines digital tools with naturopathic expertise and precision diagnostic services. This hybrid approach, complemented by subscription models and e-commerce, creates scalable revenue streams with manageable development costs.

The strategic focus on the North American market is particularly relevant for investors. High regular treatment costs and political tailwinds for preventive approaches under the current US administration favor disruptive solutions such as those offered by PanGenomic. With a current market valuation of around CAD 12.5 million and a clearly scalable business model, the Company could benefit in the long term. This is particularly true as it directly addresses the megatrends of self-optimization, data personalization, and cost efficiency. The stock has made a turnaround this year and is currently trading at CAD 0.90.

Pfizer – On the rise, but with baggage

Pfizer is showing resilience in the summer of 2025, despite pandemic-related sales continuing to decline. The latest quarterly figures were impressive due to strict cost discipline. Savings of USD 4.5 billion by the end of the year seem achievable. Despite a decline in revenue, mainly due to the slump in Paxlovid, adjusted earnings per share exceeded expectations. The Company is sticking to its forecasts for the year as a whole. Revenues are expected to be between USD 61 billion and USD 64 billion, with earnings per share ranging from USD 2.80 to USD 3.00. The operating margin is clearly benefiting from cost-cutting measures and optimized production.

Pfizer is focusing on strong therapeutic areas to close the gap left by COVID. Drugs such as Vyndaqel for the heart and its mRNA flu vaccine are showing significant growth. New approvals in oncology and rare diseases are further strengthening the portfolio. The intensive use of artificial intelligence is particularly important. AI accelerates the search for active ingredients from years to just days or months, optimizes production processes, and analyzes vast amounts of patient data for tailored personalized therapies. Partnerships with tech companies are driving this transformation forward.

Shareholders continue to appreciate the reliable dividend paid to date. The next dividend payment of USD 0.43 per share is due. A yield well above the sector average remains a key argument in favor of the stock. However, there are strong political headwinds. The "Pfizergate" scandal surrounding EU vaccine contracts is damaging the Company's image and could have regulatory consequences. In addition, there are discussions in the US about possible import tariffs and changes to vaccine compensation programs. These uncertainties are an important consideration for investors. Since the beginning of April, the stock has been slowly rising and is currently trading at USD 25.62.

The integration of artificial intelligence is becoming a key cost reducer and profit driver in the biotechnology sector. BioNTech uses AI platforms such as DeepChain and the supercomputer "Kyber" to accelerate its promising oncology pipeline and overcome losses from the post-COVID era. PanGenomic Health is fully committed to AI-based prevention with its Nustasis technology, which analyzes genetic and lifestyle data to create scalable, personalized healthcare solutions for the lucrative North American market. Pfizer is significantly advancing the use of AI in drug discovery and production to achieve efficiency gains and offset declining COVID-19 revenues with new therapies. Together, they are demonstrating how to profitably tap into the AI-driven billion-dollar markets of personalized medicine.